Celltrion’s Yuflyma (Biosimilar, Humira) Receives the US FDA’s Interchangeability Designation
Shots:
- The US FDA has granted interchangeability designation to Yuflyma, a biosimilar version of Humira (adalimumab)
- Designation was backed by P-III interchangeability trial showing comparable PK, efficacy, safety, & immunogenicity in pts with mod. to sev. PsO receiving reference adalimumab (ADA) continuously or those who alternated between ADA & Yuflyma during Wk. 25-27; data was presented at EADV 2024
- Yuflyma is a high-concentration (100mg/mL), citrate-free Humira formulation that is available in 20mg, 40mg, & 80mg doses for injection in a prefilled syringe or an autoinjector pen
Ref: Prnewswire | Image: Celltrion
Related News:- Celltrion Launches Remdantry (Biosimilar, Remicade) Across Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
